Estimating the population health and economic impacts of introducing a pneumococcal conjugate vaccine in Malaysia- an economic evaluation

References

• Cohen R, Biscardi S, Levy C. The multifaceted impact of pneumococcal conjugate vaccine implementation in children in France between 2001 to 2014. Hum Vaccin Immunother. 2016;12(2):277–84. doi:10.1080/21645515.2015.1116654.
   PubMed Web of Science ®Google Scholar
• Statistics on Causes of Deaths. Putrajaya, Malaysia: Department of Statistics; 2017 [accessed 2019 Oct 09]. https://www.dosm.gov.my/v1/index.php?r=column/pdfPrev&id=Y3psYUI2VjU0ZzRhZU1kcVFMMThGUT09.
   Google Scholar
• Wahl B, O’Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y, Luksic I, Nair H, McAllister DA, Campbell H, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15. Lancet Glob Health. 2018;6(7):e744–e57. doi:10.1016/S2214-109X(18)30247-X.
   PubMed Web of Science ®Google Scholar
• Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, Petit S, Zansky SM, Harrison LH, Reingold A, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15(3):301–09. doi:10.1016/S1473-3099(14)71081-3.
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Collins S, Djennad A, Sheppard CL, Borrow R, Fry NK, Andrews NJ, Miller E, Ramsay ME. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study. Lancet Infect Dis. 2018;18(4):441–51. doi:10.1016/S1473-3099(18)30052-5.
   PubMed Web of Science ®Google Scholar
• Shiri T, Datta S, Madan J, Tsertsvadze A, Royle P, Keeling MJ, McCarthy ND, Petrou S. Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysis. Lancet Glob Health. 2017;5(1):e51–e59. doi:10.1016/S2214-109X(16)30306-0.
   PubMed Web of Science ®Google Scholar
• GAVI. Advance Market Commitment for Pneumococcal Vaccines - Annual Report April 2014 - March 2015.
   Google Scholar
• VIEW-hub Global Vaccine Introduction Report, March 2018. International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health; 2018 Mar [accessed 2019 May 24]. www.jhsph.edu/ivac/view-hub.
   Google Scholar
• Aljunid S, Maimaiti N, Ahmed Z, Muhammad Nur A, Md Isa Z, Azmi S, Sulong S. Economic impact of Pneumococcal Protein-D Conjugate Vaccine (PHiD-CV) on the Malaysian National Immunization Programme. Value Health Reg Issues. 2014;3:146–55. doi:10.1016/j.vhri.2014.04.008.
   PubMedGoogle Scholar
• Wu DB, Roberts C, Lee VW, Hong LW, Tan KK, Mak V, Lee KK. Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong. Hum Vaccin Immunother. 2016;12(2):403–16. doi:10.1080/21645515.2015.1067351.
   PubMed Web of Science ®Google Scholar
• Wang XJ, Saha A, Zhang XH. Cost-effectiveness analysis of a universal mass vaccination program with a PHiD-CV 2+1 schedule in Malaysia. Cost Eff Resour Alloc. 2017;15:17. doi:10.1186/s12962-017-0079-2.
   PubMed Web of Science ®Google Scholar
• Aljunid S, Abuduxike G, Ahmed Z, Sulong S, Nur AM, Goh A. Impact of routine PCV7 (Prevenar) vaccination of infants on the clinical and economic burden of pneumococcal disease in Malaysia. BMC Infect Dis. 2011;11:248. doi:10.1186/1471-2334-11-248.
   PubMed Web of Science ®Google Scholar
• Wasserman M, Sings HL, Jones D, Pugh S, Moffatt M, Farkouh R. Review of vaccine effectiveness assumptions used in economic evaluations of infant pneumococcal conjugate vaccine. Expert Rev Vaccines. 2018;17:71–78. doi:10.1080/14760584.2018.1409116.
   PubMed Web of Science ®Google Scholar
• Wilson M, Wasserman M, Jadavi T, Postma M, Breton MC, Peloquin F, Earnshaw S, McDade C, Sings H, Farkouh R. Clinical and economic impact of a potential switch from 13-valent to 10-valent pneumococcal conjugate infant vaccination in Canada. Infect Dis Ther. 2018. doi:10.1007/s40121-018-0206-1.
   Web of Science ®Google Scholar
• Thorrington D, van Rossum L, Knol M, de Melker H, Rumke H, Hak E, van Hoek AJ. Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands. PLoS One. 2018;13(2):e0192640. doi:10.1371/journal.pone.0192640.
   PubMed Web of Science ®Google Scholar
• van Hoek AJ, Choi YH, Trotter C, Miller E, Jit M. The cost-effectiveness of a 13-valent pneumococcal conjugate vaccination for infants in England. Vaccine. 2012;30(50):7205–13. doi:10.1016/j.vaccine.2012.10.017.
   PubMed Web of Science ®Google Scholar
• Rhodes J, Dejsirilert S, Maloney SA, Jorakate P, Kaewpan A, Salika P, Akarachotpong T, Prapasiri P, Naorat S, Areerat P, et al. Pneumococcal bacteremia requiring hospitalization in rural Thailand: an update on incidence, clinical characteristics, serotype distribution, and antimicrobial susceptibility, 2005-2010. PLoS One. 2013;8(6):e66038. doi:10.1371/journal.pone.0066038.
   PubMed Web of Science ®Google Scholar
• 2017 National Disease Surveillance (Report 506) Nonthaburi. Thailand: Bureau of Epidemiology, Department of Disease Control, Ministry of Public Health; 2018.
   Google Scholar
• Arushothy R, Ahmad N, Amran F, Hashim R, Samsudin N, Azih CRC. Pneumococcal serotype distribution and antibiotic susceptibility in Malaysia: a four-year study (2014-2017) on invasive paediatric isolates. Int J Infect Dis. 2019;80:129–33. doi:10.1016/j.ijid.2018.12.009.
   PubMed Web of Science ®Google Scholar
• Jauneikaite E, Jefferies JM, Hibberd ML, Clarke SC. Prevalence of Streptococcus pneumoniae serotypes causing invasive and non-invasive disease in South East Asia: a review. Vaccine. 2012;30(24):3503–14. doi:10.1016/j.vaccine.2012.03.066.
   PubMed Web of Science ®Google Scholar
• Institute for Health Metrics and Evaluation. Global Burden of Disease (GBD). [accessed 2019 May 29]. http://www.healthdata.org/gbd.
   Google Scholar
• Hausdorff WP, Yothers G, Dagan R, Kilpi T, Pelton SI, Cohen R, Jacobs MR, Kaplan SL, Levy C, Lopez EL, et al. Multinational study of pneumococcal serotypes causing acute otitis media in children. Pediatr Infect Dis J. 2002;21(11):1008–16. doi:10.1097/01.inf.0000035588.98856.05.
   PubMed Web of Science ®Google Scholar
• Ahmed Z, Aljunid S, Maimaiti N, Nur A, Isa Z, Sulung S. Economic burden of pneumococcal disease in Malaysia. Abstract presented at: the 2012 APCP Conference; 2012; Kuching, Malaysia.
   Google Scholar
• Nakamura MM, Tasslimi A, Lieu TA, Levine O, Knoll MD, Russell LB, Sinha A. Cost effectiveness of child pneumococcal conjugate vaccination in middle-income countries. Int Health. 2011;3(4):270–81. doi:10.1016/j.inhe.2011.08.004.
   PubMed Web of Science ®Google Scholar
• Mittmann N, Trakas K, Risebrough N, Liu BA. Utility scores for chronic conditions in a community-dwelling population. Pharmacoeconomics. 1999;15(4):369–76. doi:10.2165/00019053-199915040-00004.
   PubMed Web of Science ®Google Scholar
• Bennett JE, Sumner W 2nd, Downs SM, Jaffe DM. Parents’ utilities for outcomes of occult bacteremia. Arch Pediatr Adolesc Med. 2000;154:43–48.
   PubMedGoogle Scholar
• Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine. 2004;22(31–32):4203–14. doi:10.1016/j.vaccine.2004.05.003.
   PubMed Web of Science ®Google Scholar
• McIntyre PB, Berkey CS, King SM, Schaad UB, Kilpi T, Kanra GY, Perez CM. Dexamethasone as adjunctive therapy in bacterial meningitis. A meta-analysis of randomized clinical trials since 1988. JAMA. 1997;278(11):925–31. doi:10.1001/jama.278.11.925.
   PubMed Web of Science ®Google Scholar
• Pomeroy SL, Holmes SJ, Dodge PR, Feigin RD. Seizures and other neurologic sequelae of bacterial meningitis in children. N Engl J Med. 1990;323(24):1651–57. doi:10.1056/NEJM199012133232402.
   PubMed Web of Science ®Google Scholar
• Cheng AK, Niparko JK. Cost-utility of the cochlear implant in adults: a meta-analysis. Arch Otolaryngol Head Neck Surg. 1999;125(11):1214–18. doi:10.1001/archotol.125.11.1214.
   PubMedGoogle Scholar
• Morrow A, De Wals P, Petit G, Guay M, Erickson LJ. The burden of pneumococcal disease in the Canadian population before routine use of the seven-valent pneumococcal conjugate vaccine. Can J Infect Dis Med Microbiol. 2007;18(2):121–27. doi:10.1155/2007/713576.
   PubMed Web of Science ®Google Scholar
• Ministry of Health Malaysia. Pharmacoeconomic Guideline For Malaysia 2012. [accessed 2019 May 20]. https://www.pharmacy.gov.my/v2/ms/dokumen/pharmacoeconomic-guideline-malaysia.html.
   Google Scholar
• Dagan R, Pelton S, Bakaletz L, Cohen R. Prevention of early episodes of otitis media by pneumococcal vaccines might reduce progression to complex disease. Lancet Infect Dis. 2016;16(4):480–92. doi:10.1016/S1473-3099(15)00549-6.
   PubMed Web of Science ®Google Scholar
• Tregnaghi MW, Saez-Llorens X, Lopez P, Abate H, Smith E, Posleman A, Calvo A, Wong D, Cortes-Barbosa C, Ceballos A, et al. Correction: efficacy of pneumococcal nontypable haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) in Young Latin American Children: a double-blind randomized controlled trial. PLoS Med. 2015;12(6):e1001850. doi:10.1371/journal.pmed.1001850.
   PubMedGoogle Scholar
• Ben-Shimol S, Givon-Lavi N, Leibovitz E, Raiz S, Greenberg D, Dagan R. Impact of widespread introduction of pneumococcal conjugate vaccines on pneumococcal and nonpneumococcal otitis media. Clin Infect Dis. 2016;63(5):611–18. doi:10.1093/cid/ciw347.
   PubMed Web of Science ®Google Scholar
• Wasserman M, Palacios MG, Grajales AG, Baez Revueltas FB, Wilson M, McDade C, Farkouh R. Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico. Hum Vaccin Immunother. 2019;15(3):560–69. doi:10.1080/21645515.2018.1516491.
   PubMed Web of Science ®Google Scholar
• Nymark LS, Sharma T, Miller A, Enemark U, Griffiths UK. Inclusion of the value of herd immunity in economic evaluations of vaccines. A systematic review of methods used. Vaccine. 2017;35(49Pt B):6828–41. doi:10.1016/j.vaccine.2017.10.024.
   PubMedGoogle Scholar
• Kim YK, LaFon D, Nahm MH. Indirect effects of pneumococcal conjugate vaccines in national immunization programs for children on adult pneumococcal disease. Infect Chemother. 2016;48(4):257–66. doi:10.3947/ic.2016.48.4.257.
   PubMed Web of Science ®Google Scholar
• Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis. 2011;11(10):760–68. doi:10.1016/S1473-3099(11)70090-1.
   PubMed Web of Science ®Google Scholar
• Meeting of the strategic advisory group of experts on immunization, October 2017 – conclusions and recommendations. [accessed 2019 May 29]. https://www.who.int/immunization/sage/meetings/2017/october/presentations_background_docs/en/.
   Google Scholar
• Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper; 2019 Feb [accessed 2019 May 29]. https://apps.who.int/iris/bitstream/handle/10665/310968/WER9408.pdf?ua=1.
   Google Scholar